Management of Allergic Diseases During COVID-19 Outbreak

• Published in: Current allergy and asthma reports 2021-02, Vol.21 (2), p.8, Article 8
• Main Authors: Izquierdo-Domínguez, Adriana, Rojas-Lechuga, María Jesús, Alobid, Isam
• Format: Article
• Language: English
• Subjects: Allergology; Asthma; Asthma - immunology; Asthma - therapy; Biological Products; Coronaviruses; COVID-19; COVID-19 - prevention & control; Dermatitis, Allergic Contact - immunology; Dermatitis, Allergic Contact - therapy; Dermatitis, Atopic - immunology; Dermatitis, Atopic - therapy; Desensitization, Immunologic; Disease Management; Disease Outbreaks; Drug Hypersensitivity - immunology; Drug Hypersensitivity - therapy; Food allergies; Food Hypersensitivity - immunology; Food Hypersensitivity - therapy; Health Personnel; Humans; Infection Control - methods; Medicine; Medicine & Public Health; Pandemics - prevention & control; Patients; Personal Protective Equipment; Physical Distancing; Rhinitis, Allergic - immunology; Rhinitis, Allergic - therapy; Rhinosinusitis (J Mullol; Rhinosinusitis (J Mullol, Section Editor); SARS-CoV-2; Section Editor; Telemedicine; Topical Collection on Rhinosinusitis
• ISSN: 1529-7322; 1534-6315; 1534-6315
• DOI: 10.1007/s11882-021-00989-x

Purpose of Review The coronavirus disease 2019 (COVID-19) has challenged healthcare system capacities and safety for health care workers, reshaping doctor-patient interaction favoring e-Health or telemedicine. The pandemic situation may make difficult to prioritize patients with allergies diseases (AD), face-to-face evaluation, and moreover concern about the possible COVID-19 diagnosis, since COVID-19 shared many symptoms in common with AD. Being COVID-19 a novel disease, everyone is susceptible; there are some advances on vaccine and specific treatment. We evaluate existing literature on allergic diseases (AD): allergic rhinitis, asthma, food allergy, drug allergy, and skin allergy, and potential underlying mechanisms for any interrelationship between AD and COVID-19. Recent Findings There is inconclusive and controversial evidence of the association between AD and the risk of adverse clinical outcomes of COVID-19. AD patients should minimize hospital and face-to-face visits, and those who have used biologics and allergen immunotherapy should continue the treatment. It is essential to wear personal protective equipment for the protection of health care workers. Summary Social distancing, rational use of facemasks, eye protection, and hand disinfection for health care workers and patients deserve further attention and promotion. Teleconsultation during COVID-19 times for AD patients is very encouraging and telemedicine platform can provide a reliable service in patient care.